Browse the evidence

Consumption of diets rich in carbohydrates promotes elevations in circulating lipids.

Practitioners should consider the impact of carbohydrate-rich diets on lipid levels.

Computer tools combine multiple components in lipid nutrition and predict balance of energy and n-3:n-6 HUFA.

These tools can enhance clinical nutrition monitoring and dietary planning.

GIPR agonism enhances the insulin-sensitizing effect of the thiazolidinedione rosiglitazone.

Incorporating GIPR agonists could enhance the effectiveness of insulin-sensitizing medications.

Anaerobic exercise decreases systemic pH and increases metabolic acidosis in athletes.

Athletes should be aware that anaerobic exercise can lead to increased metabolic acidosis.

Obese class III (OCIII) insulin users incur the greatest annual healthcare expenditures among the studied population.

Targeted interventions may be beneficial for OCIII insulin users to manage healthcare costs.

Psychotropic medications, especially antipsychotics, cause weight gain in individuals with severe mental illness (SMI).

Practitioners should be aware of the weight gain side effects of antipsychotic medications in SMI patients.

Metformin and topiramate are commonly prescribed for weight gain in individuals with SMI, but their weight loss potential is modest.

Practitioners should consider the limited effectiveness of metformin and topiramate for weight management in SMI patients.

The positive effects of the training program disappeared after 6 years.

Long-term benefits of short exercise programs may require ongoing engagement.

Current research has focused more on muscle mass than on skeletal muscle lipid metabolism.

Researchers should shift focus to skeletal muscle lipid metabolism in future studies.

Nearly half of all patients listed for kidney transplant have obesity, which is associated with increased rates of perioperative complications and graft loss.

Healthcare providers should be aware of the high prevalence of obesity in kidney transplant candidates and its implications for surgery.

Patients with cardiovascular diseases often show better survival rates with overweight and mild obesity compared to normal body weight.

Healthcare providers should consider the implications of body weight on survival in cardiovascular patients.

Protein ingestion during hemodialysis does not attenuate hemodialysis efficacy.

Protein intake can be safely incorporated into hemodialysis routines.

Higher carbohydrate intake was associated with an increased risk of total mortality (HR 1.28).

Reducing carbohydrate intake may be beneficial for longevity.

Higher saturated fat intake was associated with lower risk of stroke (HR 0.79).

Higher saturated fat intake may be protective against stroke.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

Plasma TMAO and related metabolites were not significantly associated with type 2 diabetes risk.

The findings suggest that TMAO and related metabolites may not be useful biomarkers for predicting type 2 diabetes risk.

There were no between-group differences in body composition and adaptive thermogenesis.

Practitioners should note that both diets did not significantly affect body composition or thermogenesis.

The obesity paradox was not observed among those with coronary heart disease (CHD), with an adjusted hazard ratio of 1.00 (95% CI 0.86, 1.17).

Clinicians should be cautious in applying the obesity paradox to patients with coronary heart disease.

In the intensive lifestyle intervention group, higher variability of BMI is not associated with increased risks of all-cause mortality, cardiovascular deaths, or cardiovascular events.

Intensive lifestyle interventions may mitigate the risks associated with BMI variability in patients with type 2 diabetes.

There were no significant changes in HbA1c between year 1 and year 4 for all bMVPA timing groups.

Practitioners should be aware that initial improvements in glycemic control may not persist long-term.

There was no significant change in hepatic insulin sensitivity after 6 weeks of rifaximin treatment (35.2 [15.3-51.7]% vs. 30.0 [10.8-50.5]%, P = 0.47).

Rifaximin does not appear to enhance insulin sensitivity in NASH patients.

Endoscopic hydrothermal duodenal mucosal resurfacing is well tolerated in human subjects.

Practitioners can consider this procedure as a safe option for patients.